Envestnet Asset Management
IBRX icon

Envestnet Asset Management’s ImmunityBio IBRX Stock Holding History

Envestnet Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$242K Buy
27,659
+9,513
+52% +$72K ﹤0.01% 4561
2026
Q1 		$139K Buy
+18,146
New +$124K ﹤0.01% 4578

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Asset Management's IBRX Position: Q2 2026 in Review

Envestnet Asset Management increased its ImmunityBio (IBRX) stake by 52% in Q2 2026, buying an estimated $72K and bringing the position to 27,659 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #4561.

Envestnet Asset Management first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Envestnet Asset Management held 27,659 shares of ImmunityBio worth $242K as of Q2 2026.
  • Envestnet Asset Management bought 9,513 ImmunityBio shares in Q2 2026, an estimated $72K.
  • ImmunityBio made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #4561 holding.
  • Envestnet Asset Management first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.